(TheNewswire)
-
Submission of Phase 2A/B clinicaltrials for Ethics Regulatory Approval
-
Completion of Safety Analysis ofPhase 1 Clinical Trial Data for Lysergic Acid Diethylamide (LSD) forMicrodosing Applications
Vancouver, British Columbia – TheNewswire - September 28, 2022 – Blackhawk GrowthCorp. (CSE:BLR ) ; ( Frankfurt:0JJ) (the “ Company ” or “ Blackhawk ”)subsidiary MindBio Therapeutics (“MindBio”) announces Phase 2a/bClinical Trials have been submitted for ethics and regulatoryapproval .
MindBio is working exclusively in psychedelicmicrodosing clinical trials with scientific collaborators at theUniversity of Auckland to develop intellectual property and novelmicrodosing treatments for mental health conditions that can becommercialized and used to treat patients in the primary health caresystem.
The submission for ethics approval for Phase 2A/Bclinical trials microdosing LSD in patients with Major DepressiveDisorder comes after the successful April 2022 completion of Phase 1clinical trials microdosing LSD in 80 healthy participants and NZ$1.44million funding granted from the Health Research Council of NewZealand for the Phase 2 trials. Safety data from Phase 1 Trials willbe presented at #WonderlandMiami convention,the world’s biggest psychedelics event on 4 November 2022.
In the US alone, in 2020 according to the NationalInstitute of Mental Health, an estimated 21.0 million adults had atleast one major depressive episode and 41.6% of those people soughtsome form of treatment. MindBio is developing a microdosingtreatment protocol to address this treatment challenge indepression.
“MindBio is leading the way in psychedelicmicrodosing clinical trials. The MindBio team is progressing towardsPhase 2A/B Clinical Trials and we are excited about the potential ofmicrodosing treatments to assist patients suffering from MajorDepressive Disorder.” said Frederick Pels, CEO of Blackhawk.
MindBio has been nominated in the industry awards forCompany of the Year and LSD Company of the Year and Co-Founder JustinHanka nominated for Entrepreneur of the Year and Innovator of theYear.
Investors can vote for MindBio and Co-Founder JustinHanka here
About Blackhawk Growth
Blackhawk is an investment holding company looking tocreate substantial value for its shareholders through the acquisitionand development of high growth companies. It has focused itsinvestments in the health, cannabis and cannabidiol industries in bothCanada and the United States.
For further information please contact:
Frederick Pels, Chief ExecutiveOfficer
(403)-991-7737
fred@ blackhawkgrowth.com
Cautionary NoteRegarding Forward-Looking Statement
All statements in this pressrelease, other than statements of historical fact, are “forward-looking information”with respect to the Company within the meaning of applicablesecurities laws, including with respect to transaction and futureoperations of MindBio Therapeutics Pty Ltd. The Company providesforward-looking statements for the purpose of conveying informationabout current expectations and plans relating to the future andreaders are cautioned that such statements may not be appropriate forother purposes. By its nature, this information is subject to inherentrisks and uncertainties that may be general or specific and which giverise to the possibility that expectations, forecasts, predictions,projections or conclusions will not prove to be accurate, thatassumptions may not be correct and that objectives, strategic goalsand priorities will not be achieved. These risks and uncertaintiesinclude but are not limited those identified and reported in theCompany’s public filings under the Company’s SEDAR profile atwww.sedar.com. Although the Company has attempted to identifyimportant factors that could cause actual actions, events or resultsto differ materially from those described in forward-lookinginformation, there may be other factors that cause actions, events orresults not to be as anticipated, estimated or intended. There can beno assurance that such information will prove to be accurate as actualresults and future events could differ materially from thoseanticipated in such statements. The Company disclaims any intention orobligation to update or revise any forward-looking information,whether as a result of new information, future events or otherwiseunless required by law.
About the University of Auckland
The University of Auckland is Aotearoa NewZealand’s leading university, ranked 87th in the world in the QSWorld Rankings 2022 and sixth in the Times Higher Education UniversityImpact Rankings that measure performance against the Sustainable Development Goals. High-quality research across the full range ofdisciplines, represented by its eight faculties and two Large-ScaleResearch Institutes, ensures its place among the leading internationalresearch universities.
Copyright (c) 2022 TheNewswire - All rights reserved.